QWINT 1 to 4 are treat-to-target studies in people with T2D that will assess efficacy and safety of efsitora compared to a once-daily comparator (insulin degludec or glargine U100) in combination with noninsulin glucose-lowering medications. This evidence concerns the gene INS and type 2 diabetes mellitus.